Heron Therapeutics Announces Public Offering of Common Stock
06/25/2018
|
Heron intends to use the proceeds from the proposed sale of its shares
of common stock for the commercial launch of HTX-011, if approved by the
Jefferies is acting as sole book-running manager for the offering.
The offering is being made pursuant to a registration statement that was
filed with the U.S. Securities and Exchange Commission and became
automatically effective on July 6, 2017. The securities described above
have not been qualified under any state blue sky laws. This press
release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction. Copies of the final prospectus supplement (when available)
and accompanying prospectus relating to these securities may also be
obtained by sending a request to
Forward-Looking Statements
This news release contains “forward-looking statements” as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially, including, but not limited to, those
associated with: its capital position and the sufficiency of its capital
to fund its operations in future periods; its use of the net proceeds of
the proposed public offering; and other risks and uncertainties
identified in its filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180625006206/en/
Source:
Investor Relations Contact:
Heron Therapeutics, Inc.
David
Szekeres, 858-251-4447
Senior Vice President, General Counsel,
Business Development & Corporate Secretary
dszekeres@herontx.com
and
Corporate
Contact:
Heron Therapeutics, Inc.
David Szekeres,
858-251-4447
Senior Vice President, General Counsel, Business
Development & Corporate Secretary
dszekeres@herontx.com